New publication on how cfRNA and AI are advancing LBx

New Publication - cfRNA and AI -GTC

GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune Biomarkers”. This study explores the potential of cell-free RNA (cfRNA) and AI as valuable components of liquid biopsy for evaluating the host immune system and predicting disease markers. 

The study reveals key findings: 

1. Mutation Profile and Chromosomal Abnormalities: 

   – Using a targeted RNA panel significantly more mutations were detected using cfRNA compared to cfDNA. 

   – cfRNA analysis provides comprehensive information on mutation profiling, chromosomal structural abnormalities, and fusion genes, increasing sensitivity and specificity for detecting minimal residual disease (MRD). 

2. Immune Biomarkers and Host Response: 

   – cfRNA evaluation reflects the expression levels of important genes associated with specific cancers and the host immune response. 

   – cfRNA can provide information comparable to flow cytometry analysis of hematologic neoplasms and can evaluate immune system markers in various diseases. 

3. Clinical Applications and Future Directions: 

   – Integrating cfRNA and cfDNA analysis enhances liquid biopsy capabilities. 

   – Machine learning algorithms can distinguish between normal and diseased states, predict therapy response, and develop specific diagnostic models. 

   – Larger studies are needed to confirm these findings and establish clinical applications for cfRNA-based liquid biopsy. 

This study has significant implications for liquid biopsy research and clinical practice.  


Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends